Lisata Therapeutics Announces US FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

The FDA has granted orphan drug designation to LSTA1 for use as a potential therapeutic option in patients with malignant glioma, according to an announcement from Lisata Therapeutics, Inc.